Human IL-22 R alpha 1 Alexa Fluor® 350-conjugated Antibody Summary
Accession # Q8N6P7
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
Background: IL-22 R alpha 1
IL-22 receptor, also known as IL-22 R alpha 1 and CRF2-9, is an approximately 65 kDa transmembrane glycoprotein in the type II cytokine receptor family (CRF). IL‑22 R alpha 1 contains a 211 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, and a 323 aa cytoplasmic domain. IL-22 R alpha 1 associates with either IL-10 R beta or IL-20 R beta to form receptor complexes with distinct ligand selectivities. IL-10 R beta is a shared subunit of the IL-10, -22, -26, -28, and -29 receptors, while IL-20 R beta is a shared subunit of the IL-19, -20, -22R and -24 receptors (1). IL-22 R alpha 1/IL-10 R beta is an IL-22 responsive receptor (2, 3), and IL-22 R alpha 1/IL-20 R beta is an IL-20 or IL-24 responsive receptor (4, 5). IL-22 R alpha 1 contains cytoplasmic motifs for interactions with signal transduction molecules, but formation of ternary complexes with IL-10 R beta or IL-20 R beta and the respective ligands is required for signal transduction (2, 6). IL-22BP functions as a competitive antagonist by binding IL‑22 and preventing its association with IL-22 R alpha 1 (7, 9). Even though it is a receptor for interleukins, IL-22 R alpha 1 is not expressed on hematopoietic cells (6, 10, 11). Instead, IL-22 R alpha 1 expression is restricted to epithelial and stromal cells (6, 10‑13). IL-22 R alpha 1 signaling promotes innate immune responses and wound healing at sites of infection and inflammation. This includes upregulation of antimicrobial, acute phase, proinflammatory, and extracellular matrix proteins as well as proteases (3, 11, 13, 14). IL-22 R alpha 1 signaling also promotes downregulation of proteins involved in keratinocyte differentiation (3, 14). Within the ECD, human IL-22 R alpha 1 shares 78%, 76%, and 83% aa sequence identity with mouse, rat, and canine IL-22 R, respectively. It shares 22%‑25% aa sequence identity with the ECDs of other class II receptors IL-10 R, IL-20 R, and IL-28 R.
- Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
- Xie, M.-H. et al. (2000) J. Biol. Chem. 275:31335.
- Boniface, K. et al. (2005) J. Immunol. 174:3695.
- Dumoutier, L. et al. (2001) J. Immunol. 167:3545.
- Wang, M. et al. (2002) J. Biol. Chem. 277:7341.
- Kotenko, S.V. et al. (2001) J. Biol. Chem. 276:2725.
- Li, J. et al. (2004) Int. Immunopharmacol. 4:693.
- Logsdon, N.J. et al. (2002) J. Interferon Cytokine Res. 22:1099.
- Kotenko, S.V. et al. (2001) J. Immunol. 166:7096.
- Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:577.
- Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:679.
- Aggarwal, S. et al. (2001) J. Interferon Cytokine Res. 21:1047.
- Wolk, K. et al. (2004) Immunity 21:241.
- Wolk, K. et al. (2006) Eur. J. Immunol. 36:1309.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human IL-22 R alpha 1 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human IL-22 R alpha 1 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human IL-22 R alpha 1 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image